πŸ‡ΊπŸ‡Έ FDA
Patent

US 10562952

Anti-CD276 chimeric antigen receptors

granted A61PA61P35/00

Quick answer

US patent 10562952 (Anti-CD276 chimeric antigen receptors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P35/00